A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks

Inclusion Criteria: * Male or female ≥18 years of age * Classification of SSc per the 2013 ACR/EULAR criteria. * Diagnosis or history of Raynaud's phenomenon * Minimum of 12 (maximum 100) symptomatic RP attacks documented in the ePRO diary over ≥4 separate days Exclusion Criteria: * ≥3 digital ulcers at screening; a new digital ulcer between screening and randomization; gangrene or amputation within 6 months; digital ulcer infection within 3 months. * History of cervical/digital sympathectomy or hand botulinum toxin injections within 90 days (or planned during the study). * Clinically significant bleeding risk, coagulation disorder, or platelet count \<100 x 10\^9/L. * Known WHO Group 1-5 pulmonary hypertension; significant obstructive (FEV1 \<65%) or restrictive (FVC \<60%) lung disease; need for supplemental oxygen; severe asthma. * Severe uncontrolled hypertension (SBP ≥160 and/or DBP \>100 mmHg) or severe hypotension (SBP \<85 mmHg). * Any parenteral, inhaled, or oral prostacyclin or prostacyclin receptor agonist within 12 weeks of screening; initiation/dose change of vasodilators within 4 weeks of screening; non-topical CYP2C8 inhibitors/inducers (unless discontinued for \>5 half-lives before randomization).